Article
Data presented at ACR22 shows that cycling through TNFi in axSpA patients with primary lack of efficacy with first line TNFi has limited additional benefit in controlling disease.
All News
Richard Conway
Tweet
Martínez-López et al. Higher rates of elevated transaminases with DMARD in those who previously had abnormal transaminases with isoniazid. @RheumNow #ACR22 Abstr#0816 https://t.co/xiL6DPPcw3 https://t.co/jjxRoEr8iM
Richard Conway
Tweet
Khidir et al. Lower educational level increases risk of progression of clinical suspect arthralgia to inflammatory arthritis. HR 2.35 and 5.72 in 2 cohorts. not explained by smoking, BMI or a delay in seeking medical care @RheumNow #ACR22 Abstr#0704 https://t.co/B4bm2Ihapx https://t.co/Veks0WpHLR
Eric Dein
Tweet
Ab1042 #ACR22 Ixekizumab Long-term Safety
A Deodhar: Pooled 25 studies for PsO, PsA, AS
5.4 pooled AE per 100-patient/year
0.5 IBD per 100-PY
1.3 Oral candidiasis per 100-PY
Re-assuring safety numbers. Deodhar: "These are numbers to use in clinical practice"
@RheumNow
Richard Conway
Tweet
Hamroun et al. Unfavourable pregnancy outcomes associated age, nulliparity, steroids in RA. Can only modulate the final one! @RheumNow #ACR22 Abstr#0955 https://t.co/Vob1GeMN25 https://t.co/CsVshIzp8a
Aurelie Najm
Tweet
de Hooge & al: parameters assoc w/ risk of developing syndesmophytes at 2 yrs in PsA:
Radiographic SI according to mNY = 30x higher risk
If Rx SI + CRP>6 = 100% risk devlpmt syndesmophytes @ 2 yrs.
https://t.co/CR0LymrQdr
Abs#1014 #ACR22 @Rheumnow
#ACRBest https://t.co/TLWYCJ0eYi
Richard Conway
Tweet
Rouhi @Janetbirdope et al RS3PE post checkpoint inhibitor. 11 cases. Can flare after checkpoint inhibitor reintroduction and occur following treatment. @RheumNow #ACR22 Abstr#0758 https://t.co/KCzdJvD0da https://t.co/WQ4eB2hz1k
Aurelie Najm
Tweet
Giblo et al, 1000+ pop-based cohort RA:
Cumulative incidence of depression =
Increase in cumulative incidence of anxiety 2005–14 vs. earlier decades
Despite improvements in RA ttmts. Maybe time we address these separately?
https://t.co/Z3FUgSETKW
Abs#0889 #ACR22 @Rheumnow https://t.co/Rn2ru80021
Richard Conway
Tweet
Kang @karen_kc123 et al ≥ 20 pack-years cigarette smoking associated with higher risk of incident PMR in women (HR 1.46). Every 10 pack-years associated 9% increase in risk @RheumNow #ACR22 Abstr#0698 https://t.co/t51fKFs7iJ https://t.co/IS9XC9DXl8
Richard Conway
Tweet
Maguire @Sineadm15 @rheum_covid (and me!) obstetric outcomes in RMD and COVID-19. Unvaccinated higher freq pre-term birth. Regardless of vaccine status, the women themselves did well, rarely needing pharmacotherapy @RheumNow #ACR22 Abstr#0950 #ACRbest https://t.co/GLMAAvbC4a https://t.co/kpXZbRSoMo
Aurelie Najm
Tweet
DIPSA: RCT in PsA pts w/ BMI > 25 Mediterranean diet vs. DASH-low caloric diet vs. SoC
BL: 72% obese, 42% dyslipidemia, 38% HBP, MetS 47%
Looking forward to seeing the results of this dietary intervention, MetS is high in PsA!
https://t.co/29Aq0TLANO
Abs#1007 #ACR22 @Rheumnow https://t.co/MoVYnQV6xR
Eric Dein
Tweet
Ab0411 #ACR22 Bimekizumab in AS
P3 24 wk PBO control study BE-MOBILE 2
221 BKZ, 111 PBO
Wk 16 ASAS40: BKZ 45%, 22% PBO p<0.001
Efficacy in both TNF naive and TNF failure pts
Wk 24: 1/2 pts has ASDAS<2.1
Nasopharyngitis (6%), diarrhea (4%), h/a (3.6%) 👅candidiasis (3%)
@Rheumnow https://t.co/R1ieW0FB6m
Richard Conway
Tweet
Mathew et al. Combination biologics from MarketScan. Combination less likely to have ER visit in 180 days 17% vs 23% @RheumNow #ACR22 Abstr#0768 https://t.co/Y880qDXMow https://t.co/gOH2Zlt6UV
Aurelie Najm
Tweet
CASIPSA study: retro CT SIJ analysis 48 PsA & age/sex matched ctrls.
JSN, erosion, sclerosis in 1/3 pts w/ peripheral & 1/3 pts w/ axial disease.
PsA > erosions, no diff in other parameters: lack of power or true absence of diff?
https://t.co/CR0LymrinT
Abs#1012 #ACR22 @Rheumnow https://t.co/akYYqbIFNx
Richard Conway
Tweet
Wang @zach_wallace_md et al. Machine learning can accurately classify clinical note sections as reflecting a diagnosis of AAV. As a machine learning sceptic, data like this helps (slowly) convert me. @RheumNow #ACR22 Abstr#0700 https://t.co/qbq9j9XzXG https://t.co/8iNJElI2vJ
Mike Putman
Tweet
I typically do not use mepolizumab for "vasculitic" EGPA --> recent ACR/VF guidelines agreed
Interesting study @TerrierBen suggests benefit regardless of ANCA, BVAS, VDI
Have others been using in this context or seen similar?
#ACR22 @RheumNow #ACRBest #1075 https://t.co/C6isdSn2eI
Dr. John Cush
Tweet
Are we really treating Psoriatic disease if we only address active disease domains and T2T? #ACR22
https://t.co/D3F5EzLfeP https://t.co/TO3GyZA6Lb
Md Yuzaiful Md Yusof
Tweet
#ACR22 Abstr#1654 Press Release #lupus. A cohort study using case-crossover design showed that HCQ dose =<5mg/kg actual body weight OR <400mg/day were associated with increased risk of severe #SLE flare requiring hospitalisation. Need to review Guidelines on HCQ dose @RheumNow https://t.co/5mMh7g6wcA
Janet Pope
Tweet
Toxic granules in blood vessels may damage vasculature and cause fibrosis around vessels. ‘Occult vascular disease occurs in #scleroderma, don’t forget about it’ says Wigley at Hench Memorial Lecture #ACR22 @RheumNow @ACRheum insights by a humble #SSc leader 🙏🏻 https://t.co/M82p6DwZ6Q
Dr. Rachel Tate
Tweet
AURORA 2 data VOC-treated pts w/ pure and mixed Class V lupus nephritis saw reductions in UPCR that occurred faster than in those treated with MMF and low-dose steroids alone. Abs 0355 #ACR22 @RheumNow https://t.co/eHVLDCcti8 https://t.co/jbuiOSqqsa
